Keynote & Invited Speakers
Read about our Keynote & Invited Speakers below:
Professor Megan Clowse
Professor of Medicine
Duke University School of Medicine
Durham, North Carolina, USA
Dr Megan Clowse is a Professor of Medicine and Chief of the Division of Rheumatology and Immunology; she also holds joint appointments in the Department of Obstetrics and Gynecology and Population Health Sciences. Her clinical research focuses on the management of rheumatic diseases in pregnancy. She has cared for over 1000 pregnancies in women with rheumatic disease, collecting information on these pregnancies initially in the Duke Autoimmunity in Pregnancy Registry and Repository, and the MADRA (Maternal Autoimmune Disease Research Alliance) registry and repository. She served on the Core Leadership Team for the inaugural American College of Rheumatology’s Reproductive Health Guidelines, published January 2020. Dr Clowse created www.LupusPregnancy.org and www.ReproRheum.Duke.edu, websites dedicated to improving pregnancy planning and management for patients and rheumatologists.
Dr Clowse was the founding director of the Duke Lupus Clinic, where she continues to see patients each week and mentor junior faculty researchers. The team has developed a new approach to lupus classification and management and is currently collecting and analyzing patient- and physician-reported measures to better clarify this construct.
Associate Professor Karen Schreiber Virtual Presentations
Danish Hospital for Rheumatic Diseases, Sønderborg, &
Institute for Regional Health Research
University of Southern Denmark
Dr Karen Schreiber main clinical and research interests are antiphospholipid syndrome and connective tissue diseases in pregnant women. Dr Schreiber is involved in identifying alternative treatment to improve fetal and maternal pregnancy outcomes in pregnant women with antiphospholipid syndrome. Dr Schreiber is an active member of the British Society for Rheumatology (BSR) working groups publishing clinical guidelines with the overall aim to improve the treatment of patients with rheumatic diseases.